Who are c4c?
Connect4children (c4c) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.
They endeavour to provide a sustainable, integrated platform for the efficient and swift delivery of high-quality clinical trials in children and young people across all conditions and phases of the drug development process.
c4c is a pioneering opportunity to build capacity for the implementation of multinational paediatric clinical trials whilst ensuring the needs of babies, children, young people and their families are met.
c4c has been made possible thanks to a novel collaboration between 35 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners.
c4c Network Vision
Better medicines for babies, children and young people through a pan-European clinical trial network.
c4c Network Mission
c4c will use a coordinated approach to deliver high quality “regulatory grade” clinical trials across:
Multiple countries
Multiple sites
All paediatric age groups
c4c will achieve this by:
Trial implementation using resources shared between studies
Trial design through a combination of information about natural history, feasibility, appropriate innovation, and expert opinion
Education and awareness within and beyond the network.
c4c Obectives
c4c promotes innovation in the design of paediatric clinical trials and quantitative methods in order to foster the development of new medicines in rare paediatric diseases and high medical needs areas.
c4c aims to generate a sustainable infrastructure that optimizes the delivery of clinical trials in children through:
a) a single point of contact for all sponsors, sites and investigators;
b) efficient implementation of trials, adopting consistent approaches, aligned quality standards and coordination of sites at national and international level;
c) collaboration with specialist and national networks;
d) high quality input into study design and preparation, through rigorous strategic and operational feasibility assessment;
e) the promotion of innovative trial design and quantitative scientific methods;
f) an education and training platform to shape the future leaders of paediatric drug development;
g) the development of sustainable support for all these activities.
